Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Post by StockHawk1on Jan 09, 2023 3:33pm
131 Views
Post# 35211867

AGN featured in The Power Play by The Market Herald

AGN featured in The Power Play by The Market Herald

The Power Play by The Market Herald just released this interview with Algernon Pharmaceuticals (AGN.c AGNPF) where they discuss their plans for a Phase 2b clinical study of their Ifenprodi drug for chronic cough.


The 180-patient 90-day study is set to start in Q3 of 2023.


The Phase 2a study already showed that Ifenprodil reduced cough counts in patients after 4 and 12 weeks, so I have high hopes for phase 2b.


AGN also plans to file an investigational new drug application shortly with the FDA. Great to see that AGN is quickly pushing forward with Ifenprodi. 


https://themarketherald.ca/algernon-pharmaceuticals-announces-plans-for-a-180-patient-phase-2b-chronic-cough-study-of-ifenprodil-2023-01-09/

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities